An interventional study of Novel spectacle lens design in Juvenile Myopia and Myopia, sponsored by SightGlass Vision, Inc.. Active, not recruiting at 5 sites in China. Open to participants aged 8 Years to 16 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by SightGlass Vision, Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Myopia by SightGlass Vision, Inc. — 3 open to participants now, 12 under way, none of them phase 3. Myopia · SightGlass Vision, Inc..
Among the 14 studies in Myopia by SightGlass Vision, Inc., this one is the 5th largest by planned enrollment, is one of 2 that started in 2025, is one of 14 with no phase, reaches primary completion later than 6 of the 11 other live ones, and was the 12th registered.
1,166 studies on the registry are indexed under Myopia; 228 are open to participants now.
Browse Myopia studies →3 of the 14 studies in Myopia by SightGlass Vision, Inc. are open now, in 1 country. Recruiting first, the newest first:
SightGlass Vision, Inc. · Sites in United States
Ages 6–12 · Healthy volunteers
SightGlass Vision, Inc. · Sites in United States
Ages 7–14 · Healthy volunteers
SightGlass Vision, Inc. · Sites in United States
Ages 6–8 · Healthy volunteers
By country, each count listing its studies:
Of the 124 Myopia studies recruiting now, 20 (16%) set no upper age limit and 103 (83%) stop at 75 or younger; 85 take children under 18; 53 take healthy volunteers.
This study: 8 Years to 16 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 2 started in 2025.
This study's planned enrollment of 175 is above the median of 79 across 929 interventional studies indexed under Myopia.
Median enrollment 71 across the 14 interventional studies. Of the 2 that completed or were terminated, 1 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
SightGlass Vision, Inc. is the lead sponsor of 14 studies on the registry; 3 are open to participants now.
5 of the studies in Myopia by SightGlass Vision, Inc. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07008001SightGlass Vision, Inc.Assessment of DOT Spectacles in Chinese Children Extension | 2026-12-31 |
| NCT05562622SightGlass Vision, Inc.Assessment of DOT Spectacles in Chinese Children | 2026-12-31 |
| NCT05893979SightGlass Vision, Inc.Myopia Control Spectacle Lens Cessation Study | 2026-12-31 |
| NCT06034327SightGlass Vision, Inc.Efficacy in Controlling Myopia in Young Children Using a Novel Spectacle Lens | 2027-01-31 |
| NCT07229365SightGlass Vision, Inc.Children's Viewing Behavior | 2027-04-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 14 studies in Myopia by SightGlass Vision, Inc., from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, controlled, open-label, evaluator-blinded, multicenter, clinical trial of 12-months duration to evaluate the continued safety and efficacy of Diffusion Optics Technology (DOT) spectacle lenses in reducing the progression of juvenile myopia in children of Chinese origin.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
1. Known allergy to proparacaine, tetracaine, or tropicamide or cyclopentolate
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single vision, impact-resistant spectacle lenses
Device: Novel spectacle lens design
Single vision, impact-resistant spectacle lenses
Device: Novel spectacle lens design
Use of spectacle lenses may reduce the rate of progression of juvenile myopia
Axial length Group I
Change in axial length from baseline to 36 months
Time frame: 12 months
Axial length Group II
Change in axial length from baseline to 12 months
Time frame: 12 months
Started Aug 2025 (actual). Primary completion is estimated for Dec 2026, 16 months after the start.
Of 236 industry-sponsored interventional studies with no phase under Myopia, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 24. This study's planned 16 months is above that.
Counting every sponsor, half of 438 studies reached it within 14 months; a quarter within 3 and three quarters within 34.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Sep 2026 → Dec 2026 and completion Dec 2026 → Jun 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
SightGlass Vision, Inc.